CD19 CAR-T 细胞治疗后持续性血细胞减少与克隆扩增的表达 IFN-γ 的 CD8 T 细胞的骨髓浸润相关

Autologous anti-CD19 chimeric antigen receptor T cell (CAR T) therapy is highly effective in relapsed/refractory large B cell lymphoma (rrLBCL) but is associated with toxicities that delay recovery. While the biological mechanisms of cytokine release syndrome and neurotoxicity have been investigated, the pathophysiology is poorly understood for prolonged cytopenia, defined as grade 3 cytopenia lasting beyond 30 days after CAR T infusion.

We performed single-cell RNA sequencing of bone marrow samples from healthy donors and rrLBCL patients with or without prolonged cytopenia and identified significantly increased frequencies of clonally expanded CX3CR1 hi cytotoxic T cells, expressing high interferon (IFN)- and cytokine signaling gene sets, associated with prolonged cytopenia.

In line with this, we found that hematopoietic stem cells from these patients expressed IFN- response signatures. IFN- deregulates hematopoietic stem cell self-renewal and differentiation and can be targeted with thrombopoietin agonists or IFN- -neutralizing antibodies, highlighting a potential mechanism-based approach for the treatment of CAR T-associated prolonged cytopenia.